Solvay Pharmaceuticals BV, a fortune 500 company, which had been sourcing eprosartan mesylate, an anti hyper-tension drug, manufactured by Dishman Pharmaceuticals and Chemicals Limited (Dishman) for the European markets, would now be able to sell it in the United States, as the US FDA had completed inspecting Dishman's Bavla unit, a 100% EOU.

With the order from Solvay, that would take the Indian company's blood pressure drug to the US market, Dishman sees a 40 per cent revenue rise in 2006-07.

Dishman is one of the two companies in the world with whom Solvay has entered into a long-term agreement for supply of newly developed molecule, whose patent is to expire in 2013. Solvay's order was valued at 800 million rupees. The company would supply 90 tonnes of eprosartan mesylate to Solvay in the current financial year, compared with 60 tonnes in 2005-06.

Solvay has increased the quantity of eprosartan mesylate to be supplied by Dishman by 50%.

Eprosartan mesylate is produced from three Starting Materials, whose process technology was developed by Dishman at its R & D, and Solvay having recognized the efforts put in by Dishman in this development has entered into long-term Agreement to procure these Starting Materials to manufacture eprosartan mesylate by the second supplier from whom Solvay is outsourcing its balance requirement of eprosartan mesylate.